Investment Report Reveals Medical Cures not Profitable for Big Pharma – Sick People Needed to Sustain Drug Sales

A report that made its way through the corporate sponsored "mainstream" media last week demonstrated what those of us in the alternative health media have been publishing for years: Pharmaceutical products which actually cure people are not invested in, simply because it is not a sustainable market when people are cured and no longer need Big Pharma's drugs. Investors cannot afford to invest in such products. Originally reported on CNBC.com, an April 10 report by Goldman Sachs analysts entitled "The Genome Revolution" addressed the question: "Is curing patients a sustainable business model?"

Study: Cholesterol-lowering Statin Drugs Worsen Coronary Calcium Tests

Coronary artery calcification has been found to be associated with cardiovascular events. In other words, there are more cardiovascular events when there is a higher coronary artery calcification score. The coronary calcium score can be measured with a coronary CT scan or a coronary intravascular ultrasound scan. Coronary scans are frequently ordered by cardiologists and primary care physicians. If the coronary calcium score on the CT is elevated, the doctor is most likely to prescribe a statin medication. You might think that a statin medication, if it was effective at treating and preventing heart disease, would be shown to decrease coronary calcium burden. Well, you would think wrong. Statin drugs are the most profitable drugs in the history of Big Pharma. Presently, over 28% of all U.S. adults take a statin drug. Statins are prescribed by doctors to treat high cholesterol levels and heart disease. Furthermore, the Powers-That-Be proclaim that statins will prevent a healthy person from getting heart disease. Remember, just because the Powers-That-Be continue to make the above statements does not make them true.